iBio (IBIO) Shares are Up 1.54%

iBio (IBIO) : Traders are bullish on iBio (IBIO) as it has outperformed the S&P 500 by a wide margin of 2.75% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.57%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.54% in the last 1 week, and is up 3.14% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

iBio, Inc. has dropped 2.93% during the last 3-month period . Year-to-Date the stock performance stands at 17.87%. The stock has recorded a 20-day Moving Average of 0.97% and the 50-Day Moving Average is 0.16%.


iBio (NYSEMKT:IBIO): The stock opened at $0.66 on Friday but the bulls could not build on the opening and the stock topped out at $0.68 for the day. The stock traded down to $0.65 during the day, due to lack of any buying support eventually closed down at $0.66 with a loss of -1.48% for the day. The stock had closed at $0.67 on the previous day. The total traded volume was 32,815 shares.

iBio, Inc. is a biotechnology company. The Company focuses on commercializing its platform technologies, iBioLaunch and iBioModulator, and developing select product candidates based upon these platforms. iBioLaunch is a transformative platform technology for the development and production of biologics using transient gene expression in hydroponically grown, unmodified green plants. iBioModulator is a technology platform that is designed to improve the potency and duration of effect of both prophylactic and therapeutic vaccines produced with any recombinant expression technology, including iBioLaunch. The iBio pipeline includes products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma. The Company developed its iBioModulator technology based on the use of a modified form of the cellulose degrading enzyme lichenase (LicKM), from Clostridium thermocellum.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.